Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-AL1 Study in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis

Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-AL1 Study in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis

Shots:

  • The P-III TOURMALINE-AL1 (NCT01659658) study involves assessing of Ninlaro + dexamethasone vs dexamethasone + (melphalan/ cyclophosphamide/ thalidomide/ lenalidomide)/ monothx in patients with relapsed or refractory systemic light chain (AL) amyloidosis
  •  The P-III TOURMALINE-AL1 study resulted in unmet 1EPs as well as demonstrated no improvement in overall hematologic response leading to its discontinuation
  • Ninlaro (ixazomib) is an oral proteasome inhibitor currently evaluated in multiple myeloma and is approved in 60+ countries including the US, Japan and EU with 10+ regulatory filings under review

Click here to read full press release/ article | Ref: Takeda | Image: Nikkie Asian Review